---
_id: '8232'
abstract:
- lang: eng
  text: 'Anti-epidermal growth factor receptor (EGFR) antibody therapy is used in
    EGFR expressing cancers including lung, colon, head and neck, and bladder cancers,
    however results have been modest. Near infrared photoimmunotherapy (NIR-PIT) is
    a highly selective tumor treatment that employs an antibody-photo-absorber conjugate
    which is activated by NIR light. NIR-PIT is in clinical trials in patients with
    recurrent head and neck cancers using cetuximab-IR700 as the conjugate. However,
    its use has otherwise been restricted to mouse models. This is an effort to explore
    larger animal models with NIR-PIT. We describe the use of a recombinant canine
    anti-EGFR monoclonal antibody (mAb), can225IgG, conjugated to the photo-absorber,
    IR700DX, in three EGFR expressing canine transitional cell carcinoma (TCC) cell
    lines as a prelude to possible canine clinical studies. Can225-IR700 conjugate
    showed specific binding and cell-specific killing after NIR-PIT on EGFR expressing
    cells in vitro. In the in vivo study, can225-IR700 conjugate demonstrated accumulation
    of the fluorescent conjugate with high tumor-to-background ratio. Tumor-bearing
    mice were separated into 4 groups: (1) no treatment; (2) 100 μg of can225-IR700
    i.v. only; (3) NIR light exposure only; (4) 100 μg of can225-IR700 i.v., NIR light
    exposure. Tumor growth was significantly inhibited by NIR-PIT treatment compared
    with the other groups (p < 0.001), and significantly prolonged survival was achieved
    (p < 0.001 vs. other groups) in the treatment groups. In conclusion, NIR-PIT with
    can225-IR700 is a promising treatment for canine EGFR-expressing cancers, including
    invasive transitional cell carcinoma in pet dogs, that could provide a pathway
    to translation to humans.'
article_processing_charge: No
article_type: original
author:
- first_name: Tadanobu
  full_name: Nagaya, Tadanobu
  last_name: Nagaya
- first_name: Shuhei
  full_name: Okuyama, Shuhei
  last_name: Okuyama
- first_name: Fusa
  full_name: Ogata, Fusa
  last_name: Ogata
- first_name: Yasuhiro
  full_name: Maruoka, Yasuhiro
  last_name: Maruoka
- first_name: Deborah W.
  full_name: Knapp, Deborah W.
  last_name: Knapp
- first_name: Sophia N.
  full_name: Karagiannis, Sophia N.
  last_name: Karagiannis
- first_name: Judit
  full_name: Fazekas-Singer, Judit
  id: 36432834-F248-11E8-B48F-1D18A9856A87
  last_name: Fazekas-Singer
  orcid: 0000-0002-8777-3502
- first_name: Peter L.
  full_name: Choyke, Peter L.
  last_name: Choyke
- first_name: Amy K.
  full_name: LeBlanc, Amy K.
  last_name: LeBlanc
- first_name: Erika
  full_name: Jensen-Jarolim, Erika
  last_name: Jensen-Jarolim
- first_name: Hisataka
  full_name: Kobayashi, Hisataka
  last_name: Kobayashi
citation:
  ama: Nagaya T, Okuyama S, Ogata F, et al. Near infrared photoimmunotherapy targeting
    bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.
    <i>Oncotarget</i>. 2018;9:19026-19038. doi:<a href="https://doi.org/10.18632/oncotarget.24876">10.18632/oncotarget.24876</a>
  apa: Nagaya, T., Okuyama, S., Ogata, F., Maruoka, Y., Knapp, D. W., Karagiannis,
    S. N., … Kobayashi, H. (2018). Near infrared photoimmunotherapy targeting bladder
    cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. <i>Oncotarget</i>.
    Impact Journals. <a href="https://doi.org/10.18632/oncotarget.24876">https://doi.org/10.18632/oncotarget.24876</a>
  chicago: Nagaya, Tadanobu, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Deborah
    W. Knapp, Sophia N. Karagiannis, Judit Singer, et al. “Near Infrared Photoimmunotherapy
    Targeting Bladder Cancer with a Canine Anti-Epidermal Growth Factor Receptor (EGFR)
    Antibody.” <i>Oncotarget</i>. Impact Journals, 2018. <a href="https://doi.org/10.18632/oncotarget.24876">https://doi.org/10.18632/oncotarget.24876</a>.
  ieee: T. Nagaya <i>et al.</i>, “Near infrared photoimmunotherapy targeting bladder
    cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody,” <i>Oncotarget</i>,
    vol. 9. Impact Journals, pp. 19026–19038, 2018.
  ista: Nagaya T, Okuyama S, Ogata F, Maruoka Y, Knapp DW, Karagiannis SN, Singer
    J, Choyke PL, LeBlanc AK, Jensen-Jarolim E, Kobayashi H. 2018. Near infrared photoimmunotherapy
    targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR)
    antibody. Oncotarget. 9, 19026–19038.
  mla: Nagaya, Tadanobu, et al. “Near Infrared Photoimmunotherapy Targeting Bladder
    Cancer with a Canine Anti-Epidermal Growth Factor Receptor (EGFR) Antibody.” <i>Oncotarget</i>,
    vol. 9, Impact Journals, 2018, pp. 19026–38, doi:<a href="https://doi.org/10.18632/oncotarget.24876">10.18632/oncotarget.24876</a>.
  short: T. Nagaya, S. Okuyama, F. Ogata, Y. Maruoka, D.W. Knapp, S.N. Karagiannis,
    J. Singer, P.L. Choyke, A.K. LeBlanc, E. Jensen-Jarolim, H. Kobayashi, Oncotarget
    9 (2018) 19026–19038.
date_created: 2020-08-10T11:52:54Z
date_published: 2018-04-10T00:00:00Z
date_updated: 2021-01-12T08:17:37Z
day: '10'
doi: 10.18632/oncotarget.24876
extern: '1'
intvolume: '         9'
language:
- iso: eng
main_file_link:
- open_access: '1'
  url: https://doi.org/10.18632/oncotarget.24876
month: '04'
oa: 1
oa_version: Published Version
page: 19026-19038
publication: Oncotarget
publication_identifier:
  eissn:
  - 1949-2553
publication_status: published
publisher: Impact Journals
quality_controlled: '1'
status: public
title: Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal
  growth factor receptor (EGFR) antibody
type: journal_article
user_id: 2DF688A6-F248-11E8-B48F-1D18A9856A87
volume: 9
year: '2018'
...